Inactive Instrument
Company Progenics Pharmaceuticals, Inc.
Stocks
US7431871067
Biotechnology & Medical Research
Business description: Progenics Pharmaceuticals, Inc.
Sales by Activity: Progenics Pharmaceuticals, Inc.
| Fiscal Period: December | 2019 (USD) |
|---|---|
Pharmaceuticals | 34.99M |
Executive Committee: Progenics Pharmaceuticals, Inc.
| Manager | Title | Age | Since |
|---|---|---|---|
David Mims
CEO | Chief Executive Officer | 62 | - |
Company details: Progenics Pharmaceuticals, Inc.
Bio Therapeutic Drugs
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +0.21% | -4.63% | +55.34% | +71.32% | 68.92B | |
| +1.66% | +7.51% | +8.12% | +60.04% | 51.9B | |
| +3.14% | +7.17% | +12.48% | +44.42% | 48.73B | |
| +3.45% | +4.70% | +33.44% | +35.96% | 43.13B | |
| -2.20% | +0.61% | +281.88% | +532.76% | 41.48B | |
| +6.43% | +6.84% | +18.32% | +109.23% | 39.96B | |
| +1.28% | +1.39% | +11.69% | +45.10% | 30.6B | |
| +2.51% | -7.41% | +36.01% | +1.76% | 26.01B | |
| +1.74% | -2.02% | -13.55% | -12.92% | 22.27B | |
| Average | +2.02% | -0.94% | +49.30% | +98.63% | 41.44B | |
| Weighted average by Cap. | +1.91% | -0.25% | +52.82% | +105.49% |
